PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary Malignancies

Salem, Alaa; Fine, Gerald; Covington, Matthew F.; Koppula, Bhasker R.; Wiggins, Richard H.; Hoffman, John M.; Morton, Kathryn A.

doi:10.3390/cancers14123000

Cited by 15 publications

(21 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Первичный рак влагалища является редким заболеванием и составляет менее 2% всех гинекологических злокачественных новообразований, при этом плоскоклеточный рак является наиболее распространенным подтипом [55]. ПЭТ/КТ c ФДГ, как было показано, выявляет первичную карциному и метастазы в лимфатических узлах с высокой диагностической точностью [56]. Тем не менее, когда злокачественное новообразование встречается во влагалище, оно, скорее всего, связано с метастазированием путем контагиозного распространения (>80%) из соседних органов в репродуктивном тракте (чаще карциномы шейки матки) и прямой кишке, другие первичные локализации встречаются крайне редко.…”

Section: влагалищеunclassified

“…Большие половые губы являются основным местом в подавляющем большинстве случаев рака вульвы. На ранних стадиях заболевания чувст вительность и специфичность ПЭТ/КТ с ФДГ в выявлении поражения лимфатических узлов в паху составляет 53 и 85% [56]. На более поздних -сооб щают об отличной эффективности ПЭТ/КТ с ФДГ для паховых узлов с чувствительностью 100% и специфичностью 85%, с отсечкой SUV max 4,5 или значением, в два раза превышающим среднее значение SUV (SUV mean ) печени.…”

Section: вульваunclassified

“…На более поздних -сооб щают об отличной эффективности ПЭТ/КТ с ФДГ для паховых узлов с чувствительностью 100% и специфичностью 85%, с отсечкой SUV max 4,5 или значением, в два раза превышающим среднее значение SUV (SUV mean ) печени. Если есть ограничения на биопсию сторожевого лимфатического узла, ПЭТ/КТ с ФДГ может играть роль в оценке поражения тазовых лимфатических узлов [56]. Перед планируемой операцией по экзентерации малого таза ПЭТ/КТ с ФДГ может сыграть роль в исключении отдаленных метастазов.…”

Section: вульваunclassified

See 2 more Smart Citations

The role of PET/CT in oncogynecology (literature review)

Николаева

Тарачкова

Шейх

et al. 2023

Medicinskaâ vizualizaciâ

View full text Add to dashboard Cite

Purpose: to consider the modern possibilities of positron emission tomography combined with computed tomography (PET/CT) with FDG in the diagnosis of oncological formations in gynecology.Materials and methods. Search, selection and evaluation of existing foreign and domestic research included in the peer-reviewed E-library, PubMed, GoogleScholar, Scopus.Results. This article summarizes the existing evidence base to establish the clinical relevance and new possibilities for the use of FDG PET/CT in common gynecological malignancies.Conclusion. The use of FDG PET/CT can have a significant impact on patient management by improving cancer staging, influencing patient choice for treatment, and detecting early disease recurrence.

show abstract

Section: влагалищеunclassified

Section: вульваunclassified

See 1 more Smart Citation

The role of PET/CT in oncogynecology (literature review)

Николаева

Тарачкова

Шейх

et al. 2023

Medicinskaâ vizualizaciâ

View full text Add to dashboard Cite

show abstract

“…However, it is always difficult for patients with recurrence and metastasis to obtain tumor tissues. 2-Deoxy-2-[ 18 F] fluoro-D-glucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) is acknowledged as an important non-invasive whole-body molecular imaging modality for evaluation of various tumors [ 7 , 8 , 9 , 10 , 11 , 12 ]. It has been reported that 18 F-FDG PET/CT could be used to predict multiple molecular phenotypes for malignant tumors, for instance, HER2 expression in gastric cancer [ 13 ], EGFR mutations and positive ALK expression in NSCLC [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Retrospective Analysis of the Predictive Value of 18F-FDG PET/CT Metabolic Parameters for PD-L1 Expression in Cervical Cancer

Pang

Song

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Background: Immunotherapy targeting PD-1/PD-L1 has been proven to be effective for cervical cancer treatment. To explore non-invasive examinations for assessing the PD-L1 status in cervical cancer, we performed a retrospective study to investigate the predictive value of 18F-FDG PET/CT. Methods: The correlations between PD-L1 expression, clinicopathological characteristics and 18F-FDG PET/CT metabolic parameters were evaluated in 74 cervical cancer patients. The clinicopathological characteristics included age, histologic type, tumor differentiation, FIGO stage and tumor size. The metabolic parameters included maximum standard uptake (SUVmax), mean standard uptake (SUVmean), total lesion glycolysis (TLG) and tumor metabolic volume (MTV). Results: In univariate analysis, SUVmax, SUVmean, TLG, tumor size and tumor differentiation were obviously associated with PD-L1 status. SUVmax (rs = 0.42) and SUVmean (rs = 0.40) were moderately positively correlated with the combined positive score (CPS) for PD-L1 in Spearman correlation analysis. The results of multivariable analysis showed that the higher SUVmax (odds ratio = 2.849) and the lower degree of differentiation (Odds Ratio = 0.168), the greater probability of being PD-L1 positive. The ROC curve analysis demonstrated that when the cut-off values of SUVmax, SUVmean and TLG were 10.45, 6.75 and 143.4, respectively, the highest accuracy for predicting PD-L1 expression was 77.0%, 71.6% and 62.2%, respectively. The comprehensive predictive ability of PD-L1 expression, assessed by combining SUVmax with tumor differentiation, showed that the PD-L1-negative rate was 100% in the low probability group, whereas the PD-L1-positive rate was 84.6% in the high probability group. In addition, we also found that the H-score of HIF-1α was moderately positively correlated with PD-L1 CPS (rs = 0.51). Conclusions: The SUVmax and differentiation of the primary lesion were the optimum predictors for PD-L1 expression in cervical cancer. There was a great potential for 18F-FDG PET/CT in predicting PD-L1 status and selecting cervical cancer candidates for PD1/PD-L1 immune checkpoint therapy.

show abstract

“…PSMA is a membrane antigen that is overexpressed in the majority of PC cells and it is an ideal target for PC diagnosis and therapy (theranostics). In particular, PSMA-targeted PET/CT or PET/MRI (using PSMA-targeting radiopharmaceuticals labelled with 68 Ga, 18 F, or 64 Cu) is gaining importance in the staging and restaging of PC [ 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. The accurate diagnosis of bone metastases is relevant in guiding local and systemic treatment in PC.…”

mentioning

confidence: 99%